We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
From the FDA.
- Abstract
The article reports on the issuance of an Early Communication by the U.S. Food and Drug Administration (FDA) on the possible link between suicidal behavior and the use of asthma medication Singulair (Montelukast). The agency found that there is no evidence of a causal relationship between suicide risk and the asthma medication. The FDA has approved extended-release fluvoxamine (Luvox CR) for treating social anxiety disorder (SAD) and obsessive-compulsive disorder (OCD) in adults.
- Subjects
UNITED States; ANTIASTHMATIC agents; DRUG side effects; DRUG approval; ANXIETY disorders treatment; MENTAL health services; OBSESSIVE-compulsive disorder; SOLVAY Pharmaceuticals Inc.; UNITED States. Food &; Drug Administration
- Publication
Brown University Psychopharmacology Update, 2008, Vol 19, Issue 6, p8
- ISSN
1068-5308
- Publication type
Article